Monday 27 April 2009

Well Done !!!

"The Bob Tolley Dominoe Team" have won the Eastbourne League. So Well done to them all and a big thank you for all your support. A more detailed report will follow with photographs from the presentation night which is due to be arranged shortly.

Monday 20 April 2009

Bart's Mesothelioma Research

Bart’s Mesothelioma Research: is a group of doctors, nurses and laboratory researchers aiming to improve the treatment and increase our understanding of mesothelioma and lung cancer. Mesothelioma is the main type of cancer caused by asbestos poisoning. Mesothelioma and other asbestos-related illnesses such as lung cancer and pleural plaques are increasing in incidence even though asbestos was little used after 1980. The problem is that there is a delay of between 30 and 50 years from the exposure to asbestos dust and the development of one of the diseases.
Britain is currently facing an epidemic of asbestos-related illness. Unfortunately there is very little research going on into mesothelioma in the UK. Bart’s Mesothelioma Research is aiming to raise the profile of this neglected group of diseases by offering our patients the best possible treatment and by conducting first-rate clinical and laboratory research.
At Bart’s we have one of the largest outpatient clinics in the UK for patients with mesothelioma. Typically our doctors see two or three new patients weekly. We also see a large number of patients who have completed treatment and are being followed up. We take a very positive view of treatment for mesothelioma and our patients are treated as individuals with treatment tailored accordingly. Treatments that we use include chemotherapy, radiotherapy and surgery. All patients are assessed in detail for symptoms by our team which also includes cancer specialist nurses. www.mesothelioma.co.uk

Bart's Mesothelioma Clinical Trials

Clinical Trials and Chemotherapy
Irinotecan, mitomycin and cisplatin (‘IPM’) for the first-line or second-line treatment of pleural mesothelioma.
This intensive chemotherapy treatment causes cancer shrinkage in around 30-40% of patients with mesothelioma. Side effects can include lack of energy, nausea and hair loss. The treatment is given every two weeks as an outpatient. Not all patients are suitable for IPM treatment but many patients have benefited from the tumour shrinkage achievable.
Weekly vinorelbine chemotherapy for the first-line or second-line treatment of pleural mesothelioma.
This less-toxic chemotherapy treatment causes cancer shrinkage in around 20% of patients with mesothelioma. Side effects can include lack of energy, nausea and constipation. The treatment is given weekly as an outpatient. Patients sometimes respond to vinorelbine chemotherapy after previous different chemotherapy treatment.
Weekly vinorelbine chemotherapy for the first-line treatment of peritoneal mesothelioma.
Patients with peritoneal mesothelioma have a similar chance of benefit as patients with pleural mesothelioma.. We offer weekly vinorelbine chemotherapy as our treatment for patients with peritoneal mesothelioma.
We also offer all other conventional mesothelioma treatments. New clinical trials are in development all the time so please go to our website for updates. www.mesothelioma.co.uk

Bart's Mesothelioma Research

Laboratory Research Programme - Introduction
The Bart's laboratory programme is aiming to understand the biology of malignant mesothelioma.
The main interests of our laboratory group are:

  • The study of apoptotic mechanisms and sites of drug resistance in malignant mesothelioma.
Apoptosis, or "programmed cell death", is the regulatory process by which damaged cells are destroyed. There are at least two known apopotic pathways - the "intrinsic" and the "extrinsic", both of which involve the activation of a family of proteins called caspases. Under normal cell activity, activation of caspases leads to apoptosis. In tumours, disruptions in these pathways cause resistance to apoptosis and ensure cell survival and development.
With the use of tissue and molecular biology techniques, we are trying to identify dysfunctional proteins in the mesothelioma apoptotic pathway and sites of drug resistance.
The protein identified might be novel targets for effective treatment.

The genetics of malignant pleural mesothelioma.


Mesothelioma cell-line studies and state of the art genomic array technology is used to identify alterations in the mesothelioma genome and provide information for target therapy.

Thursday 2 April 2009

Charity Event 2009

The Bob Tolley Mesothelioma Snowdrop Fund
Charity Event
Saturday 26th September 2009
Golf Competition "The Bob Tolley Golf Trophy"
Horam Park Golf Club
Followed by An Auction, Raffle, Disco & Buffet
Eastbourne United Football Club
The Oval Channelview Road Eastbourne
All Proceeds to Mesothelioma Research